GO:0002158 osteoclast proliferation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002158 osteoclast proliferation describes the multiplication or reproduction of osteoclasts, the specialized bone-resorbing cells that expand from monocyte-derived precursors.
• RANKL and OPG signaling are the central cytokine pathways controlling osteoclast differentiation and the size of the osteoclast precursor pool.
• Interleukin-6 can transiently promote proliferation of osteoclast precursors while also stimulating inflammatory mediators.
• ATF3 and FTO are established regulators of osteoclast precursor proliferation and apoptosis in bone remodeling and inflammatory conditions.
• Osteoclast proliferation is clinically relevant to postmenopausal osteoporosis, inflammatory bone loss, craniofacial morphogenesis, and osteosarcoma progression.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are key tools for dissecting genes that control osteoclast proliferation.
Description
Osteoclast proliferation (GO:0002158) is the biological process by which osteoclasts multiply or reproduce, leading to expansion of an osteoclast cell population. Osteoclasts are specialized phagocytic cells that absorb and remove the mineralized matrix of bone tissue and typically differentiate from monocytes. Because the size of the osteoclast pool directly influences bone resorption, understanding the signals that drive osteoclast proliferation is central to bone biology and to diseases of excess or insufficient bone loss. The process is not simply a generic cell-cycle event; it is embedded in a cytokine network in which RANKL and OPG set the differentiation and activation tone, while factors such as interleukin-6 and CSF1R influence precursor expansion. Recent work has also linked osteoclast proliferation to broader developmental and pathological programs, including neural crest proliferation during craniofacial morphogenesis and osteosarcoma progression. As a result, GO:0002158 is a useful annotation for researchers who need to distinguish proliferation of osteoclast lineage cells from differentiation, fusion, or resorptive activity. This article summarizes the authoritative QuickGO definition, the major molecular players, disease connections, and the experimental models and methods used to study osteoclast proliferation.
osteoclast proliferation At A Glance
| GO ID | GO:0002158 |
|---|---|
| GO term | osteoclast proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Multiplication or reproduction of osteoclasts, expanding the osteoclast cell population |
| Cell type | Osteoclast, a specialized phagocytic cell that absorbs and removes mineralized bone matrix |
| Typical origin | Monocytes |
| Related process | Osteoclast differentiation and bone resorption |
| Key signaling context | RANKL and OPG signaling pathways |
What Is GO:0002158?
According to the QuickGO definition, osteoclast proliferation is the multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue, which typically differentiates from monocytes. In practical terms, this GO term captures the proliferative expansion step of the osteoclast lineage rather than the later steps of multinucleation, polarization, or bone resorption.
Why Is osteoclast proliferation Important in Cell Biology?
Osteoclast proliferation is important because the number of osteoclasts is a major determinant of bone resorption capacity, and its dysregulation contributes to skeletal disease. RANKL and OPG signaling pathways are the principal regulators of osteoclast differentiation and activity, and they set the context in which osteoclast precursors expand. Interleukin-6 can transiently promote proliferation of osteoclast precursors and stimulate inflammatory mediators, linking osteoclast proliferation to inflammatory bone loss. ATF3 controls proliferation of osteoclast precursors and bone remodeling, showing that transcriptional regulators can directly tune the size of the osteoclast pool. In postmenopausal osteoporosis, estrogen deficiency is associated with altered osteoclast proliferation, and CRNDE has been implicated in this process. Beyond bone, osteoclast proliferation is relevant to osteosarcoma progression and to craniofacial morphogenesis, where CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation. Thus, GO:0002158 sits at the intersection of bone homeostasis, inflammation, development, and cancer.
• Controls the size of the osteoclast population and therefore the bone resorption capacity.
• Is regulated by the RANKL/OPG signaling axis, a central pathway in bone metabolism.
• Can be transiently promoted by interleukin-6, connecting osteoclast proliferation to inflammation.
• Is modulated by ATF3, a transcription factor that controls osteoclast precursor proliferation and bone remodeling.
• Is influenced by FTO, which regulates proliferation and apoptosis of osteoclast precursors in inflammatory conditions.
• Is implicated in postmenopausal osteoporosis through estrogen deficiency and CRNDE.
• Is linked to osteosarcoma progression, where PPARG and an integrin α2-osteoclast axis have been described.
• Is relevant to craniofacial morphogenesis, where CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation.
• Provides a mechanistic target for therapies aimed at bone destruction in cancer and inflammatory disease.
• Is a useful annotation for distinguishing osteoclast lineage expansion from differentiation and resorption.
What Happens During osteoclast proliferation?
Origin from monocyte-derived precursors
In simple terms: Osteoclasts start as monocyte-like precursor cells that can divide before they become mature bone-resorbing cells.
Osteoclasts typically differentiate from monocytes, and the osteoclast lineage begins with precursor cells that retain proliferative capacity. The QuickGO definition of GO:0002158 explicitly frames osteoclast proliferation as the multiplication or reproduction of osteoclasts, resulting in expansion of an osteoclast cell population, and notes that osteoclasts are specialized phagocytic cells associated with absorption and removal of the mineralized matrix of bone tissue. This precursor stage is the point at which the population can expand before terminal differentiation and fusion.
RANKL and OPG signaling set the proliferative context
In simple terms: RANKL and OPG are the main cytokine signals that tell osteoclast precursors whether to expand and differentiate.
RANKL and OPG signaling pathways are the principal regulators of osteoclast differentiation, and they establish the cytokine environment in which osteoclast precursors proliferate and mature. Because OPG acts as a decoy receptor for RANKL, the RANKL/OPG ratio influences the extent of osteoclast lineage expansion. This pathway is therefore a central reference point for interpreting experiments on GO:0002158.
Interleukin-6 transiently promotes precursor proliferation
In simple terms: Inflammatory signals such as interleukin-6 can briefly push osteoclast precursors to divide more.
Interleukin-6 transiently promotes proliferation of osteoclast precursors and stimulates the production of inflammatory mediators. This finding links osteoclast proliferation to inflammatory conditions and helps explain why inflammatory bone loss can involve expansion of the osteoclast precursor pool. The transient nature of the effect suggests that timing and duration of cytokine exposure are important experimental variables.
Transcriptional and epitranscriptomic control by ATF3 and FTO
In simple terms: Certain proteins such as ATF3 and FTO act as brakes or accelerators on osteoclast precursor division.
ATF3 controls proliferation of osteoclast precursors and bone remodeling, indicating that this transcription factor directly regulates the proliferative step of the osteoclast lineage. FTO regulates osteoclast development by modulating the proliferation and apoptosis of osteoclast precursors in inflammatory conditions, adding an epitranscriptomic layer of control. Together, these studies show that osteoclast proliferation is not a passive consequence of cytokine signaling but is actively tuned by intracellular regulators.
Expansion of the osteoclast population and downstream bone resorption
In simple terms: Once the osteoclast population expands, more cells are available to resorb bone.
The outcome of osteoclast proliferation is an expanded osteoclast cell population, which increases the potential for bone resorption. In disease settings, this expansion can contribute to bone destruction, as illustrated by the integrin α2-osteoclast axis in osteosarcoma. In postmenopausal osteoporosis, estrogen deficiency is associated with effects on osteoclast proliferation, and CRNDE has been implicated in this process. Thus, GO:0002158 represents an upstream control point for bone-resorbing capacity.
Developmental and non-skeletal roles
In simple terms: Osteoclasts and related macrophages can also influence how other tissues, such as the face skeleton, develop.
CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis, showing that osteoclast lineage cells can influence developmental proliferation programs beyond bone resorption. In osteosarcoma, single-cell RNA sequencing revealed that PPARG promoted osteosarcoma progression based on osteoclast proliferation, linking GO:0002158 to cancer biology. These findings broaden the relevance of osteoclast proliferation to development and oncology.
Key Genes Involved in GO:0002158 osteoclast proliferation
The following genes and proteins have been experimentally linked to osteoclast proliferation or to the osteoclast lineage context in which this process occurs.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFSF11 (RANKL) | Central cytokine that drives osteoclast differentiation and lineage expansion | Core pathway for studying osteoclast proliferation and bone remodeling |
| TNFRSF11B (OPG) | Decoy receptor that modulates RANKL signaling | Determines the RANKL/OPG ratio that influences osteoclast population size |
| IL6 | Inflammatory cytokine that transiently promotes osteoclast precursor proliferation | Links inflammation to osteoclast precursor expansion |
| ATF3 | Transcription factor controlling osteoclast precursor proliferation | Regulates bone remodeling through the proliferative step |
| FTO | Epitranscriptomic regulator of proliferation and apoptosis in osteoclast precursors | Connects RNA modification to osteoclast development in inflammation |
| CRNDE | Long non-coding RNA implicated in osteoclast proliferation under estrogen deficiency | Model for postmenopausal osteoporosis research |
| PPARG | Nuclear receptor linked to osteosarcoma progression via osteoclast proliferation | Single-cell RNA sequencing target in osteosarcoma |
| CSF1R | Receptor for macrophage and osteoclast lineage cells | Depletion impairs neural crest proliferation and craniofacial morphogenesis |
| ITGA2 (integrin α2) | Integrin subunit in the integrin α2-osteoclast axis | Therapeutic target in osteosarcoma bone destruction |
| NFATC1 | Master transcription factor of osteoclast differentiation | Downstream effector of RANKL signaling in osteoclast lineage |
| CTSK | Cathepsin K, a bone-resorbing enzyme of mature osteoclasts | Marker of osteoclast function downstream of proliferation |
| ACP5 (TRAP) | Tartrate-resistant acid phosphatase, osteoclast marker | Used to identify osteoclast lineage cells in proliferation studies |
| MITF | Transcription factor involved in osteoclast lineage regulation | Candidate regulator of osteoclast precursor biology |
| PU.1 (SPI1) | Transcription factor required for osteoclast lineage commitment | Upstream regulator of osteoclast precursor identity |
| V-ATPase subunits | Proton pump components for bone resorption | Functional marker of mature osteoclasts after proliferation |
| MMP9 | Matrix metalloproteinase secreted by osteoclasts | Marker of osteoclast activity in bone remodeling |
| TRAF6 | Signaling adaptor downstream of RANK | Mediates RANKL-dependent osteoclast lineage signals |
| SRC | Kinase involved in osteoclast function | Downstream effector in osteoclast biology |
How Is osteoclast proliferation Regulated?
Osteoclast proliferation is regulated by the RANKL and OPG signaling pathways, which control osteoclast differentiation and the balance between bone formation and resorption. Interleukin-6 can transiently promote proliferation of osteoclast precursors and stimulate inflammatory mediators, providing a cytokine-level regulatory input. ATF3 controls proliferation of osteoclast precursors and bone remodeling, acting as an intracellular transcriptional regulator. FTO regulates osteoclast development by modulating proliferation and apoptosis of osteoclast precursors in inflammatory conditions, adding an epitranscriptomic regulatory layer. Estrogen deficiency in postmenopausal osteoporosis is associated with altered osteoclast proliferation, and CRNDE has been implicated in this regulation. In cancer, PPARG and the integrin α2-osteoclast axis have been linked to osteoclast proliferation and bone destruction in osteosarcoma. Together, these studies indicate that osteoclast proliferation is controlled by a combination of cytokine, transcriptional, epitranscriptomic, and hormonal inputs.
osteoclast proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CRNDE | Postmenopausal osteoporosis with altered osteoclast proliferation | Knockdown or overexpression in osteoclast precursor cultures under estrogen deficiency |
| IL6 | Inflammatory bone loss with transient osteoclast precursor proliferation | Cytokine stimulation of osteoclast precursors with proliferation assays |
| FTO | Inflammatory osteoclast development via proliferation and apoptosis | Knockout or point-mutation models in osteoclast precursors |
| PPARG | Osteosarcoma progression linked to osteoclast proliferation | Single-cell RNA sequencing and knockout in osteosarcoma models |
| ITGA2 | Osteosarcoma bone destruction via integrin α2-osteoclast axis | Knockout or blocking antibody models in bone tumor studies |
Postmenopausal osteoporosis
Estrogen deficiency in postmenopausal osteoporosis is associated with changes in osteoclast proliferation, and CRNDE has been reported to impact the proliferation of osteoclasts in this condition. Because osteoclast proliferation expands the pool of bone-resorbing cells, it is mechanistically relevant to the bone loss observed after menopause. The RANKL/OPG signaling axis remains the central pathway for understanding how osteoclast numbers are controlled in this disease context.
Inflammatory bone loss
Interleukin-6 transiently promotes proliferation of osteoclast precursors and stimulates the production of inflammatory mediators, linking osteoclast proliferation to inflammatory conditions. FTO regulates osteoclast development by modulating proliferation and apoptosis of osteoclast precursors under inflammatory conditions, further connecting this process to inflammation. These findings suggest that inflammatory cytokines and epitranscriptomic regulators can cooperate to expand the osteoclast precursor pool.
Osteosarcoma and bone destruction
Single-cell RNA sequencing revealed that PPARG promoted osteosarcoma progression based on osteoclast proliferation, directly linking GO:0002158 to cancer. The integrin α2-osteoclast axis has been described as a key driver of bone destruction and a therapeutic target in osteosarcoma. These studies position osteoclast proliferation as a potential target in the tumor microenvironment of bone cancers.
Craniofacial development
CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis, indicating that osteoclast lineage cells influence developmental proliferation programs. This finding extends the relevance of osteoclast proliferation beyond skeletal homeostasis to embryonic development of the face. It also highlights the importance of macrophage and osteoclast populations in tissue morphogenesis.
From osteoclast proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene control osteoclast precursor proliferation? | CRISPR knockout in monocyte-derived osteoclast precursor cells |
| Does a specific point mutation alter osteoclast proliferation? | CRISPR point-mutation knock-in in osteoclast lineage cells |
| Does a disease-associated variant affect osteoclast population expansion? | Knock-in of the variant followed by proliferation assays |
| Where is a protein of interest expressed during osteoclast proliferation? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a gene expand the osteoclast pool? | Overexpression in osteoclast precursors with proliferation readouts |
| Does a gene influence osteoclast proliferation in inflammatory conditions? | Knockout or overexpression under interleukin-6 or inflammatory stimulation |
How to Study the osteoclast proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Proliferation assay | Division and expansion of osteoclast precursors | Testing cytokine or gene effects on osteoclast proliferation |
| Single-cell RNA sequencing | Transcriptional programs in individual osteoclast lineage cells | Discovering regulators such as PPARG in osteosarcoma |
| Apoptosis assay | Cell death in osteoclast precursors | Distinguishing proliferation from survival effects of FTO |
| Osteoclast marker staining | Presence of osteoclast lineage cells | Confirming cell identity in proliferation experiments |
| CRISPR knockout | Loss-of-function effects on osteoclast proliferation | Testing candidate genes such as ATF3 |
| CRISPR knock-in | Effect of specific variants or tags | Modeling disease variants in osteoclast lineage |
| Overexpression | Gain-of-function effects on osteoclast population size | Testing genes such as CRNDE or PPARG |
| Bone histomorphometry | Osteoclast numbers and bone remodeling in vivo | Validating proliferation findings in bone tissue |
Proliferation assays in osteoclast precursors
Proliferation of osteoclast precursors can be measured directly in culture systems, as shown by studies in which interleukin-6 transiently promoted precursor proliferation. ATF3 was shown to control proliferation of osteoclast precursors and bone remodeling using such approaches. These assays are typically combined with osteoclast lineage markers to confirm cell identity.
Single-cell RNA sequencing
Single-cell RNA sequencing revealed that PPARG promoted osteosarcoma progression based on osteoclast proliferation, demonstrating the power of this method for linking gene expression programs to osteoclast proliferation in complex tissues. This approach can resolve osteoclast lineage cells from other cell types in the tumor microenvironment. It is also useful for identifying new regulators of GO:0002158.
Apoptosis and proliferation co-analysis
FTO regulates osteoclast development by modulating both proliferation and apoptosis of osteoclast precursors in inflammatory conditions, illustrating the value of measuring these two processes together. Co-analysis helps distinguish changes in population size due to increased division from those due to reduced cell death. This is important for accurate interpretation of GO:0002158 experiments.
Genetic and pharmacologic perturbation
CRNDE impacts the proliferation of osteoclasts in estrogen deficiency, and the integrin α2-osteoclast axis has been targeted in osteosarcoma, showing that genetic and pharmacologic perturbation can be used to test causality. RANKL and OPG pathway components provide additional perturbation points for osteoclast proliferation studies. Such experiments help establish whether a candidate gene is required for osteoclast population expansion.
How CRISPR Can Be Used to Study GO:0002158 osteoclast proliferation
Knockout
CRISPR knockout is used to test whether a candidate gene is required for osteoclast proliferation. For example, ATF3 controls proliferation of osteoclast precursors and bone remodeling, and knockout approaches can confirm such requirements. FTO knockout can reveal effects on proliferation and apoptosis of osteoclast precursors in inflammatory conditions. Knockout of RANKL/OPG pathway components provides a way to dissect the central signaling axis of osteoclast proliferation.
Point Mutation
CRISPR point mutation allows researchers to introduce specific amino acid changes or disease-associated variants into genes that regulate osteoclast proliferation. This is particularly useful when a variant is suspected to alter precursor proliferation without fully abolishing gene function. Point-mutation models can help distinguish effects on proliferation from effects on differentiation or apoptosis.
Knock-in
Knock-in models can be used to express tagged proteins or disease-relevant alleles in osteoclast lineage cells. Tagged knock-in enables visualization of proteins during osteoclast proliferation and can confirm expression in precursor populations. Knock-in of variants in genes such as FTO or CRNDE can test their causal role in altered osteoclast proliferation.
Overexpression
Overexpression models test whether increasing the level of a gene expands the osteoclast population. CRNDE overexpression or knockdown has been used to study osteoclast proliferation in estrogen deficiency. PPARG-related osteoclast proliferation in osteosarcoma has been investigated with expression-based approaches. Overexpression of cytokines such as interleukin-6 can also transiently promote osteoclast precursor proliferation.
How EDITGENE Supports osteoclast proliferation Research
Researchers studying osteoclast proliferation-related genes often need to determine whether a candidate gene is causally involved in precursor expansion, differentiation, or bone resorption. EDITGENE provides CRISPR-based cell model services that allow precise perturbation of genes in the osteoclast lineage, from complete knockout to subtle point mutations and tagged knock-ins. These models support mechanistic studies of GO:0002158 and its links to osteoporosis, inflammation, osteosarcoma, and craniofacial development.
Contact EDITGENE today to design your custom CRISPR model for osteoclast proliferation research.
Frequently Asked Questions About osteoclast proliferation
What is osteoclast proliferation?
Osteoclast proliferation (GO:0002158) is the multiplication or reproduction of osteoclasts, resulting in expansion of an osteoclast cell population. Osteoclasts are specialized phagocytic cells that absorb and remove the mineralized matrix of bone tissue and typically differentiate from monocytes.
What genes are involved in osteoclast proliferation?
Key genes include TNFSF11 (RANKL) and TNFRSF11B (OPG) in the central signaling axis, IL6, ATF3, FTO, CRNDE, PPARG, CSF1R, and ITGA2, among others.
How is osteoclast proliferation regulated?
It is regulated by RANKL and OPG signaling, inflammatory cytokines such as interleukin-6, transcription factors such as ATF3, epitranscriptomic regulators such as FTO, and hormonal factors in estrogen deficiency.
What is the role of RANKL in osteoclast proliferation?
RANKL and OPG signaling pathways are the principal regulators of osteoclast differentiation and set the cytokine context for osteoclast lineage expansion.
How does interleukin-6 affect osteoclast proliferation?
Interleukin-6 transiently promotes proliferation of osteoclast precursors and stimulates the production of inflammatory mediators.
What is the connection between osteoclast proliferation and osteoporosis?
In postmenopausal osteoporosis, estrogen deficiency is associated with altered osteoclast proliferation, and CRNDE has been implicated in this process.
How is osteoclast proliferation studied in the lab?
Common methods include proliferation assays, single-cell RNA sequencing, apoptosis assays, osteoclast marker staining, CRISPR knockout or knock-in, overexpression, and bone histomorphometry.
Can CRISPR be used to study osteoclast proliferation?
Yes. CRISPR knockout, point mutation, knock-in, and overexpression models are used to test whether specific genes control osteoclast precursor proliferation and population expansion.
Is osteoclast proliferation important in cancer?
Yes. Single-cell RNA sequencing revealed that PPARG promoted osteosarcoma progression based on osteoclast proliferation, and the integrin α2-osteoclast axis drives bone destruction in osteosarcoma.
What is the difference between osteoclast proliferation and differentiation?
Osteoclast proliferation refers to multiplication or reproduction of osteoclasts and expansion of the population, whereas differentiation refers to the process by which monocyte-derived precursors acquire osteoclast identity.
Conclusion
Osteoclast proliferation (GO:0002158) is the process by which osteoclasts multiply and expand, a step that determines the size of the bone-resorbing cell pool. It is controlled by RANKL and OPG signaling, inflammatory cytokines such as interleukin-6, transcriptional regulators such as ATF3, and epitranscriptomic factors such as FTO. Its dysregulation is linked to postmenopausal osteoporosis, inflammatory bone loss, osteosarcoma progression, and craniofacial development. Researchers can now dissect the causal roles of specific genes using CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with proliferation assays and single-cell approaches.
References
- 1. Udagawa N et al.. 2021. Osteoclast differentiation by RANKL and OPG signaling pathways.. J Bone Miner Metab 39(1):19-26 PMID: 33079279
- 2. Sun L et al.. 2024. Single-cell RNA sequencing revealed PPARG promoted osteosarcoma progression: based on osteoclast proliferation.. Front Immunol 15:1506225 PMID: 39936154
- 3. He J et al.. 2024. FTO regulates osteoclast development by modulating the proliferation and apoptosis of osteoclast precursors in inflammatory conditions.. Cell Signal 117:111098 PMID: 38365111
- 4. Chang PY et al.. 2022. Interleukin-6 transiently promotes proliferation of osteoclast precursors and stimulates the production of inflammatory mediators.. Mol Biol Rep 49(5):3927-3937 PMID: 35218446
- 5. Fukasawa K et al.. 2016. ATF3 controls proliferation of osteoclast precursor and bone remodeling.. Sci Rep 6:30918 PMID: 27480204
- 6. Ma F et al.. 2026. CSF1R+ macrophage and osteoclast depletion impairs neural crest proliferation and craniofacial morphogenesis.. Development 153(16) PMID: 41891183
- 7. Li W et al.. 2018. CRNDE impacts the proliferation of osteoclast by estrogen deficiency in postmenopausal osteoporosis.. Eur Rev Med Pharmacol Sci 22(18):5815-5821 PMID: 30280760
- 8. Wei H et al.. 2025. The integrin α2-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma.. J Transl Med 23(1):1204 PMID: 41174632
